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Abstract 
Purpose: To develop processes for effective isolation and purification of recombinant human 
plasminogen activator (rhPA) from transgenic rabbit milk. 
Methods: Immunoaffinity chromatography was selected and improved by a special polyol-responsive 
monoclonal antibody (PR-mAb). Alteplase was used as immunogen because of its similarity to rhPA in 
terms of structure. The PR-mAb was prepared by hybridoma technology and screened by ELISA-elution 
assay. Screening antibody was performed using rhPA milk in an ELISA-elution assay. The antibody 
clone C4-PR-mAb was selected for immunoaffinity chromatography. The rhPA was effectively bound to 
immobilized C4-PR-mAb on the column and was eluted with Tris buffer comprising 0.75 mol/L 
ammonium sulfate and 40n% propanediol (pH7.9). The rhPA was further purified by passing through 
Chromdex75 gel filtration column. 
Results: There were 12 hybridoma strains selected into the polyol-responsive mAbs screen step and 
three hybridoma strains were superior for producing PR-mAbs (C1, C4, C8). The rhPA can be purified 
from transgenic rabbit milk and maintained a higher thrombolytic activity in vitro by FAPA. 
Conclusion: The results demonstrate the suitability of the alternative approach used in this study. 
Using immunoaffinity chromatography and gel filtration column is feasible and convenient for extracting 
rhPA from milk, and should be useful for purifying other tPA mutants or other novel recombinant milk-
derived proteins.  
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Natural human tissue plasminogen activator 
(tPA) is secreted by vascular endothelial cells 
displaying thrombolytic activity. Currently on the 
market, clinical tPA is used for treating acute 
myocardial infarction, brain death, pulmonary 
embolism, deep venous thrombosis, and other 
thrombotic diseases and is produced by 
prokaryotic or eukaryotic cell expression system 
(e.g., CHO) [1-3]. Some modifications on 
molecular structure have resulted in recombinant 
tPA (rtPA or rhPA) with better bioactive 
characters, such as higher specificity to 
thrombus, longer half-life in blood, and less 
amount of bleeding [1,2]. However, commonly 
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used processes for rhPA are based on 
prokaryotic or eukaryotic vector which impose 
many limitations on rhPA development, i.e., its 
technology and cost [1,4]. 
 
To increase the half-life and thrombolytic activity 
of tPA-type drugs, a novel tPA mutant (rhPA) 
was designed by our research team. With only 
K2 and P structure domain, it was different from 
Alteplase, which contains F, E, K1, K2, and P 
domains. It was produced by using a transgenic 
rabbit mammary gland bioreactor, which may be 
a popular approach for expressing recombinant 
foreign protein more safely. This bioreactor also 
produces higher output than prokaryotic or 
eukaryotic cell expression system. If its purity is 
further improved, and its activity is preserved in 
the manufacturing process, rhPA has great 
potential as a new application in thrombolytic 
medicine. However, effective purification for this 
novel recombinant protein is needed. 
 
Many methods of protein extraction from milk 
have been studied [5,6], among which immuno 
affinity chromatography(IAC) is a convenient and 
efficient approach because of its simple one-step 
operation and high specificity to target protein 
[7,8]. However, a strongly acidic buffer (pH is 
less than or equal to 3.0) is often used to elute 
and dissociate the target protein, which was not 
beneficial in protecting the molecular 
conformation and bioactivity of rhPA.  
 
In order to preserve the functional domains, it 
would be best to assemble an affinity column that 
allows protein dissociation from immobilized 
ligand. Polyol-responsive monoclonal antibody 
(PR-mAb) is a kind of special ligand that can 
release the target protein from the IAC column 
gently and easily [8]. The application of PR-mAbs 
to the affinity column would improve the defects 
because of its slightly alkaline elution buffer 
instead of strong acidic condition, consisting of 
Tris buffer with ammonium sulfate and propylene 
glycol (pH7.9) which have little damage to protein 
stability [9]. 
 
Preparation of specific antibodies is very 
important in affinity technology; finding a suitable 
immunogen is a key link. Alteplase, a commercial 
drug, can be used as immunogen for anti-rhPA 
antibodies, which has a structure similar to that 
of rhPA and can be obtained with high purity (> 
99 %).However, to prepare specific antibody for 
rhPA, Alteplase was used as the immunogen. 
After conducting the Elisa-elution screening 
method, three strains of PR-mAbs were 




This study was approved by the Institutional 
Animal Care and Use Committee of Yangzhou 
University (China) and performed according to 
the Guide for the care and use of laboratory 
animals [10]. Chemicals were purchased from 
Sigma Chemical Co. and China unless otherwise 
specified. 
 
Immunization and hybridoma cell culture 
 
Six-week old BALB/c mice were immunized by 
Alteplase (purchased from Subei People's 
Hospital of Jiangsu province, China). 
QuickAntibodyTM immunologic adjuvant was used 
to enhance the immune response of Alteplase, 
mixed with Alteplase of 1:1 volume. Each mouse 
was injected intramuscularly with 5 μg mixture of 
Alteplase-QuickAntibody twice, at an interval of 
21 days. At 14 days after the secondary 
immunization, booster injection was given 
intramuscularly with Alteplase-PBS solution at 10 
μg per mouse. Three days after booster injection, 
the mouse that presented higher serum level of 
antibodies was selected for cell fusion. 
 
Electro fusion technique was used in cell fusion. 
However, spleen cells and myeloma cells were 
mixed at a ratio of 1:1 and fused in electro fusion 
solution (0.3 M mannitol, 0.1 mM CaCl2, and 0.1 
mM MgCl2) using cell fusion generator. The 
distance between the two electrodes was 2 mm. 
Membrane fusion was performed by three 
electrical pulses; first with alternating current at 
40 V for 30 s and then with two times of direct 
current at 325 V (162.5 V/mm) for 30 μsat an 
interval time of 0.5 s. The fused cells were 
centrifuged (800 g, 5min) and the cell pellets 
were suspended with HAT/DMEM medium and 
planted into 96-well platespre-coated with feeder 
cells. 
 
Screening for anti-rhPA mAbs 
 
Indirect ELISA was used here. The rhPA milk 
whey of transgenic rabbit was immobilized to 
ELISA plate as the detecting antigen. In another 
ELISA plate, the normal rabbit milk whey was 
immobilized as control antigen to exclude the 
false positive results that would be caused by the 
nonspecific binding of antibodies to other 
components from rabbit whey. The supernatant 
of each cell culture was the primary antibody, 
SP20 cell culture acted as negative control, and 
PBS acted as blank control. After three times 
subcloning by limited dilution assay, positive 
hybridoma could be determined. 
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Screening for PR-mAbs 
 
ELISA-elution assay was performed as described 
previously [12]. Here, the rhPA milk whey was 
immobilized, cross-reacting with the primary 
antibody (supernatant of positive hybridoma 
cells) for 2 h at 37 °C. SP20 cell culture acted as 
negative control, and PBS acted as blank control. 
After washing, Tris buffer containing 0.75 M 
ammonium sulfate and 40 % (v/v) propylene 
glycol (pH 7.9) was added to each sampling hole 
and kept at room temperature (24 °C) for 20 min 
to dissociate the binding of antibody to antigen. 
The secondary antibody (HRP conjugated goat 
anti-mouse IgG antibody) was diluted with 
dilution buffer (PBS with 1 % FBS) at a volume 
ratio of 1:2000. After color development, each 
well was read by microplate reader at 450 nm. 
 
Large scale preparation and purification for 
PR-mAb 
 
Eight-week old multiparous BALB/c mice were 
intraperitoneally injected with 0.5 mL liquid 
paraffin,followed by the PR-mAb hybridoma cells 
of 5 × 106 cells per mouse 1 week later. After 5 
days, peritoneal fluid was collected and purified 
by ProteinA affinity column.  
 
Preparation for immunoaffinity column 
 
The purified antibody was dialyzed with 3.5 KDa 
molecular weight cutoff dialytic-bags against 
coupling buffer (0.2 M NaHCO3, 0.5 M NaCl) 
overnight at 4 °C and concentrated via 
PEG20000. This antibody solution was 
transferred to the CNBr activated Sepharose for 
conjugation. The process was performed at room 
temperature (24 °C) overnight, whereas the 
uncoupled CNBr groups were blocked in the 
blocking buffer (20 mM Tris-HCl, pH 8.3) for 4 h 
at the same temperature. Before the resin could 
be used, 0.05 M Tris-HCl (pH 8.5) and 0.2 M 
acetate (pH 4.6) were used to wash the mAb-
Sepharosesix times alternately. Finally, 
precooled PBS was transferred to suspend the 
resin.  
 
Purification of rhPA using the immunoaffinity 
column 
 
Before application to the IAC, milk sample was 
processed as follows rabbit milk was centrifuged 
(8,000 rpm) at 4 °C for 30 min and the 
supernatant of whey was separated from 
transgenic rabbit milk; 35 % saturated 
ammonium sulfate was added to the supernatant 
for precipitating the rhPA component and then 
the pellet was dialyzed with 3.5 KDa molecular 
weight cutoff dialytic-bags against PBS overnight 
at 4 °C. 
 
After pretreatment on milk, the crude sample was 
run on the C4-PR-mAb coupled column. AKTA 
explorer system with UV detector (280 nm), 
sample loops, fraction collector and analysis 
software was used in the IAC. The packed 
column was washed and equilibrated with PBS at 
1 mL/min. The crude rhPA solution was loaded 
into the column at a flow speed of 1 mL/min and, 
PBS used to elute the unbinding proteins out of 
the affinity column. When the flow through the 
baseline was stable, elution buffer (TE buffer with 
0.75 mol/L ammonium sulfate and 40 % 
propanediol, pH 7.9) was run on the IAC at 1 
mL/min to dissociate the rhPA from the mAb-
sepharose. The peak fractions were collected 
and analyzed by SDS-PAGE.  
 
Further purification of rhPA using gel 
filtration chromatography  
 
Chromdex 75 prep grade gel filtration was used 
to remove the other large proteins. IAC 
processed sample was run on the gel filtration 
column and eluted with PBS (pH 7.4) at 1 
mL/min. The other proteins with larger molecular 
weight passed through the column first, and the 
rhPA fraction followed. 
 
Purity, antibody cross-reactivity and 
thrombolytic activity of the purified rhPA 
 
SDS-PAGE was used to analyze the purity of 
rhPA product from immunoaffinity step and gel 
filtration step.  
 
The unstained gel was applied in Western blot 
analysis to identify the rhPA. However, the gel 
was transferred to the 0.45 micrometers PVDF 
membrane in transfer buffer at 1 mA/cm2 for 3.5 
h, Furthermore, the membrane was placed in 
blocking buffer at 4 °C overnight. The primary 
antibody was the purified PR-mAb, which was 
diluted at 1:5000 in PBS and incubated with 
membrane at 37 °C for 1.5 h. The secondary 
antibody conjugated with HRP was added and 
held at 37 °C for 1.5 h. After washing thrice with 
washing buffer, DAB substrate solution was used 
for blot development, and incubation was done 
for 20 min at room temperature (24 °C). 
 
ELISA was used to determine the antibody 
cross-reactivity of each fraction collected from 
the chromatography process. Procedure for this 
test was similar to the antibody screening 
section. However, the coating antigen was 
replaced with each fraction of chromatography, 
and the primary antibody was replaced with the 
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purified PR-mAb. The other operations were the 
same as the part of antibody screen. 
 
Fibrin agarose plate assay (FAPA) was carried 
out to evaluate the thrombolytic activity of the 
purified rhPA. Fibrin-thrombin-agarose gel (100 
mL) was composed of 1 g agarose, 1 g 
fibrinogen, and 100 U thrombin dissolved in PBS. 
Agarose was brought to a boil, and after cooling 
to 45 °C, boiled agarose was immediately mixed 
with fibrinogen and thrombin (37 °C). The warm 
mixture was then dispensed into Plexiglass 
dishes. When the solution cooled to room 
temperature, fibrin-thrombin-agarose solidified to 
a gel state. Sample wells were drilled in each gel 
and filled with 20 μL sample solution. In 
thrombolytic step, each dish was incubated at 37 
°C overnight. The activity was determined by the 




Data analysis was performed by descriptive 
analysis and standard curve using SPSS 21 




Preparation of anti-rhPA monoclonal 
antibody 
 
QuickAntibodyTM adjuvant was used in mouse 
immunization. After boost immunization, the 
serum titer reached 1:1010. In this study, the 
dose of immunogen was reduced to 20μg per 
mouse, and the experimental days were 
shortened to 35 days. Improvements in immune 
dose and period were observed with the above 
mentioned procedure compared with the 
common Freund's adjuvant procedure.   
 
A total of 814 hybridoma clones appeared in a96-
well plate. Standard ELISA was used to screen 
positive cell strains producing antibodies that 
could react with the coating antigen, rabbit milk, 
which contained rhPA. After three times of 
subcloning, 12 hybridoma strains were selected 
for the polyol-responsive mAbs screen step. 
 
Screening of polyol-responsive monoclonal 
antibody 
 
The 12 positive hybridomas detected in standard 
ELISA were rescreened here. Comparing the OD 
value of the two kinds of ELISA, the wells with a 
significantly decrease in OD were considered to 
contain polyol responsive mAbs. According to 
Table1, three hybridoma strains were superior in 
terms of producing PR-mAbs, as follows: C1, C4, 
and C8. The values of D-OD reached 5 0 % 
[10,12]. 
 
C4 hybridoma strain was selected to prepare the 
PR-mAb for immunoaffinity ligand. ProteinA 
column was used to purify the C4 PR-mAb from 
mouse ascites. 
 
Immunoaffinity purity of rhPA in rabbit milk 
 
SDS-PAGE gel showed the sample with other 
two bands at 55–70KDa, which were not the 
molecular weight of rhPA (Figure 1). This result 
suggested that the fraction contained proteins, 
but not rhPA. 
 
Therefore, gel filtration chromatography was 
applied to separate the other unrelated proteins. 
According to the principle of molecular sieve, the 
large protein was first passed through the 
column. rhPA, which had smaller molecular 
weight was considered in the second peak b 
(Figure 2). SDS-PAGE showed the peak b 
fraction only with a single band, and the band 
was allocated at 39 KDa, which was the 
molecular weight of rhPA (Figure 1). Further 
determination of crosslink activity for the fraction 
of peak b was performed by Western Blot (Figure 
1). The results suggested that the target protein 
rhPA was contained in the second peak b. 
 
Table 1: ELISA-elution of polyol-responsive monoclonal antibody to rhPA  
 






































































































The coating antigen is transgenic rabbit milk. SP20 cell acted as negative control. PBS acted as blank control. 
OD1 is the optical density of standard ELISA. OD2 is the optical density of ELISA-elution. △OD is equal to OD2 
minus OD1; D-OD is equal to△OD/OD1*100% 
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Figure 1: SDS-PAGE and Western Blot analysis in the purification of rhPA. Note: Part A, from 1 to 7, the 
electrophoresis bands arewhey of transgenic rabbit milk, whey of normal non-transgenic rabbit milk, product of 
affinity chromatography, peak a in gel filtration chromatography, peak b in gel filtration chromatography, and PBS 
respectively; Part B, from 1 to M, the electrophoresis bands were PBS, water, whey of normal non-transgenic 
rabbit milk, whey of transgenic rabbit milk, products in affinity chromatography, peak a in gel filtration 
chromatography, peak b in gel filtration chromatography, and the protein of molecular weight standards 
 
 
Figure 2: Gel filtration chromatogram. PBS (pH 7.4) 
was the elution buffer at 1 mL/min flow velocity 
 
Activity of purified rhPA 
 
FAPA was applied to evaluate the thrombolytic 
bioactivity of purified rhPA in vitro, and the index 
was the diameter size of the fibrinolysis ring. As 
shown in Fig 3, well 10 contained the purified 
rhPA at a concentration of 1 μg/mL, and the 
thrombolytic activity was presented with 24.0 mm 
diameter of the fibrinolysis ring. The purified 
rhPA (1 μg/mL concentration) was presented 
with 24.0 mm diameter of the fibrinolysis ring of 
thrombolytic activity. A standard curve (Fig 3) 
was drawn using the concentrations of Alteplase, 
as follows: 5000, 1000, 200, 40, 8, 1.6, 0.32 and 
0 µg/mL. To reach the same thrombolytic effect 
of rhPA, the concentration of Alteplase was 
supposed to be 214 µg/mL, which was much 
higher than the dose of purified rhPA. Thus, this 
purified rhPA displayed a 214-fold increase in 
activity to dissolve thrombus, compared with 
Alteplase by FAPA. 
 




















Figure 3: The standard curve of Alteplase in 
thrombolytic bioactivity. X-axis: the concentration of 
Alteplase (lg μg/mL); Y-axis: the diameter size of the 
fibrinolysis ring (mm). The concentrations of Alteplase 




rhPA is our originally designed mutant of tPA. 
This recombinant protein was produced by a 
bioreactor, rabbit mammary gland, which has 
advantages in natural molecular structure, 
protein amount, and safety. However, purification 
of the recombinant protein from milk is not an 
easy process [13]. Immunoaffinity chromate-
graphy is widely adopted, but the commonly 
used elution buffers often contain an acid agent 
or a chaotropic reagent, which would reduce the 
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activity of target protein [14-16]. As for rhPA, its 
bioactivity relies on its protein structure. 
Therefore, a gentle method for purifying rhPA is 
necessary. In this study, immunoaffinity 
chromatography coupled with polyol responsive 
mAb was used. PR-mAbs as immunoaffinity 
ligands have been reported, and these presented 
good performance on RNA polymerase and RNA 
polymerase II [9-11,15]. However, these have not 
been used in the extraction for rabbit milk 
protein. This paper described the preparation for 
PR-mAbs and the application of the C4-PR-mAb 
in immunoaffinity chromatography for rhPA 
purification. 
 
Three steps were required in this purification 
research. The first step involved extracting crude 
sample from rabbit milk, using salting out, 
ultrafiltration, and dialysis. The second step 
included immunoaffinity chromatography with 
C4-PR-mAb; rhPA and rhPA purity were not 
high. The other two bands appeared obviously 
(Fig. 1A). Thus, we initially suspected that C4-
PR-mAb crosslinked with other proteins and not 
only rhPA. However, the normal rabbit milk could 
not cross-react with the serum antibody of the 
immunized group, and this was also impossible 
for C4-PR-mAb (25 and 50 KDa). Therefore, if 
our first hypothesis was true, it would explain the 
following: except for rhPA, another novel protein 
was expressed by the transgenic rabbit. 
However, this explanation did not have a reliable 
basis. Fig 1A was worth mentioning again. The 
band at 64 KDa may have resulted from the 
combination of rhPA and the light chain of the 
antibody (39 KDa + 25 KDa = 64 KDa). The band 
at 50 KDa may be the heavy chain of antibody 
(50 KDa). This is not a coincidence because 
antibody ligand falling off column in affinity 
chromatography often occurred. Thus, in Fig 1B, 
the two fractions with negative reactivity for C4-
PR-mAb may be related to the rhPA epitopes 
covered by the C4-PR-mAb ligand, which was 
detached from the column. rhPA with a single 
molecular was our objective. Thus, through 
Chromdex 75 prep grad gel filtration 
chromatography, these two bands were 





C4-PR-mAb is the key factor in this 
immunoaffinity purification for rhPA. rhPA is a 
novel recombinant mutant protein without F, E, 
and K1 structure domain, but the structure is 
similar to that of Alteplase. Based on this point, 
Alteplase is creatively selected as immunogen. 
The rhPA can be purified from transgenic rabbit 
milk through the above-described method, and it 
displayed 214-fold higher activity in dissolving 
thrombus than Alteplase. This process for 
antibody and purification development is our 
original design and helps us to determine rhPA 
PR-mAbs. Meanwhile, we successfully purified 
rhPA from milk. This method would be useful for 
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